Some biological products used to treat psoriasis may be associated with an increased risk for skin cancer and other malignancies, according to a recent report from the Institute for Safe Medication Practices (ISMP) publication, QuarterWatch.
Although no definitive causal link is claimed, experts are urging increased vigilance for the cancer signal in patients taking certain psoriasis medications—a billion-dollar therapeutic category for specialty pharmacy, according to the latest industry